![]() |
![]() |
![]() |
![]() |
47-P | A survey of regional anaesthetic practice in immune and gestational thrombocytopenia in pregnancy | Marwa Salman | ![]() |
![]() |
|||
49-P | Audit of the use of chest X-rays in the management of adult neutropenic sepsis at Kings College Hospital, London | CY Zhu | ![]() |
![]() |
|||
51-P | Anticoagulation in patients undergoing cardioversion at Hampshire Hospitals NHS Foundation Trust | Sufyan Benamer | ![]() |
![]() |
|||
52-P | A study of the implementation of romiplostim & eltrombopag in the NHS in England | Lisa Cooper | ![]() |
![]() |
|||
53-P | Evaluation of the body fluid mode on the XE-5000 for counting leukocytes in bronchoalveolar lavage fluid | Lucie Gruchalova | ![]() |
![]() |
|||
55-P | The impact of formal chemotherapy training on haematology registrars | Joanna Collins | ![]() |
![]() |
|||
56-P | Formalising palliative care education augments clinical skills in haematology trainees | Rosanna Ghinai | ![]() |
![]() |
|||
58-P | Idiopathic systemic capillary leak syndrome treated successfully with maintenance intravenous immunoglobulin | Andrew King | ![]() |
![]() |
|||
59-P | Management of the Choose and Book system for polycythaemia/thrombocytosis by the MPN specialist nurse | Louise Wallis | ![]() |
![]() |
|||
61-P | The development and review of performance assessment scoring in blood films for parasites external quality assessment | Paul McTaggart | ![]() |
![]() |
|||
62-P | Second line treatment for immune thrombocytopenia (ITP): A review of patients with ITP in Basildon Hospital | Katie White | ![]() |
![]() |
|||
72-P | New conclusions in scintigraphy results of sickle cell disease bone involvements | Hasan Al-Jafar | ![]() |
![]() |
|||
76-P | Annual British Society for Haematology confidential survey of bone marrow examination associated adverse events 2013 | Vinod Devalia | ![]() |
![]() |
|||
81-P | The use of thrombopoeitin (TPO) as a Biomarker in Immune Thrombocytopenia (ITP) | George Adams | ![]() |
![]() |
|||
82-P | The effects of Triton-X on haematological assays when used as an inactivator for Ebola virus | Alexander Gatt | ![]() |
![]() |
|||
83-P | A case report may lead to addendum to BSH treatment guideline of acquired VWD | Hassan Al-Jafar | ![]() |
![]() |
|||
87-P | Recurrence of VTE over four years: Local outcome data to determine and compare location of VTE events for hospital or community acquired VTE | Huw Rowswell | ![]() |
![]() |
|||
88-P | Direct oral anti-coagulants for prevention of stroke and systemic embolism in non-valvular atrial fibrillation Barts Health experience across two sites | Pallavi Kalkur | ![]() |
![]() |
|||
90-P | A double-centre retrospective study into rates of postpartum haemorrhage in women on low molecular weight heparin | Rachel Browne | ![]() |
![]() |
|||
91-P | Acute nurse-led VTE service reduces admission and facilitates NOAC use for VTE | Marianna Koperdanova | ![]() |
![]() |
|||
93-P | Audit of the effect of the introduction of a guideline for the management of superficial vein thrombosis to a nurse-led DVT clinic | Charlotte Grimley | ![]() |
![]() |
|||
94-P | Evaluation of pathology quality assurance review recommendations: Data from a UK NEQAS for Blood Coagulation (UK NEQAS BC) questionnaire | Shelene Munroe-Peart | ![]() |
![]() |
|||
99-P | Review of factor XI deficiency: Bleeding phenotype and clnical considerations | Philip George | ![]() |
![]() |
|||
103-P | Cancer-associated VTE occurring over one year in a small district general hospital | Emma Harris | ![]() |
![]() |
|||
104-P | Patients with suspected TTP should be acutely managed in a critical care setting | Jennifer Burgess | ![]() |
![]() |
|||
108-P | Thrombopoietin-receptor agonists in immune thrombocytopaenic purpura: Our experience at East Kent Hospitals University NHS Foundation Trust | Kate Fletcher | ![]() |
![]() |
|||
120-P | Burden of venothromboembolism and thromboprophylaxis at East Kent Hospitals NHS Foundation Trust in patients with myeloma treated with immunomodulatory drugs (IMid) containing regimens between 2009 and 2014: A retrospective study | Catherine Roughley | ![]() |
![]() |
|||
121-P | Prospective audit of rivaroxaban as thromboprophylaxis and treatment during myeloma therapy with immunomodulatory drugs (IMiDs) at East Kent Hospitals NHS Foundation Trust | Catherine Roughley | ![]() |
![]() |
|||
123-P | MGUS Tracker an alternative way of monitoring MGUS outside the haematology clinic | Heather Eve | ![]() |
![]() |
|||
127-P | An audit of compliance with the NICE guideline for the use of lenalidomide therapy in patients with myeloma | ANANDIKA LIYANAGE | ![]() |
![]() |
|||
128-P | Significant gender differences in the number and distribution of T cells in patients with mantle cell lymphoma | Nimish Shah | ![]() |
![]() |
|||
132-P | Rare, fulminant presentations of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma a case series | Xiao-Yin Zhang | ![]() |
![]() |
|||
134-P | Outcomes from a single centre for patients with multiply relapsed myeloma treated with bendamustine containing regimens | Noel Ryman | ![]() |
![]() |
|||
139-P | Audit of central nervous system (CNS) prophylaxis in patient with diffuse large B-cell lymphoma (DLBCL) | Abdul Baseer Qadri | ![]() |
![]() |
|||
142-P | Life-threatening bowel perforation while on thalidomide-based triplet regimen for multiple myeloma: A retrospective case series | Priya Sriskandarajah | ![]() |
![]() |
|||
148-P | Off trial use of brentuximab vedotin in Hodgkin lymphoma a regional experience | Joseph Browning | ![]() |
![]() |
|||
156-P | Retrospective observational study of patients with relapsed/refractory myeloma treated with pomalidomide - the UK Experience | Priya Sriskandarajah | ![]() |
![]() |
|||
165-P | Real world efficacy of pomalidomide for relapsed myeloma - a multicentre restrospective study | Matthew Wells | ![]() |
![]() |
|||
181-P | Optimisation of RNA extraction and RT-qPCR for the quantification of AID in archived FFPE biopsy samples: only two sections of 4 micrometre tissue are required | Omar Alishlash | ![]() |
![]() |
|||
187-P | Efficacy of azacitidine in the treatment of acute myeloid leukaemia (blasts 30) in comparison to MDS | John Gaffney | ![]() |
![]() |
|||
188-P | Investigating differences in serum and plasma values in galactomannan testing, signal loss and sources of false positivity | Naeem Desai | ![]() |
![]() |
|||
191-P | Frequency and management of breakthrough fungal infections in patients with acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL) on antifungal prophylaxis | Claire Burney | ![]() |
![]() |
|||
193-P | Single centre experience in the use of pegylated interferon alpha for myeloproliferative neoplasms | Meghna Ruparelia | ![]() |
![]() |
|||
199-P | Convenient care for patients: A real world evaluation to describe the NHS impact of administering velcade R (bortezomib) in a home setting for patients with multiple myeloma | Samantha Oliver | ![]() |
![]() |
|||
201-P | Alternate day lenalidomide as a well-tolerated and cost-effective treatment in multiple myeloma | Yeong Jer Lim | ![]() |
![]() |
|||
204-P | CALR mutations in myeloproliferative neoplasm related splanchnic vein thrombosis | Mallika Sekhar | ![]() |
![]() |
|||
206-P | How well are patients with myeloproliferative neoplasms assessed for cardiovascular risk: An audit report | Mallika Sekhar | ![]() |
![]() |
|||
220-P | Seroprevalence of undiagnosed transfusion transmissible infections (HIV, hepatitis B and C and syphilis) in donated blood in National Blood Banks, Khartoum, Sudan | doaa yousif | ![]() |
![]() |
|||
224-P | The impact of maternal allo-antibodies on the clinical outcomes of foetuses/neonates at Barts Health NHS Trust | Jessica Jardim | ![]() |
![]() |
|||
226-P | Incidence of Rh and Kell blood group antigens among blood donors in Qatar | Ibrahim Mustafa | ![]() |
![]() |
|||
227-P | Consent to long-term multiple blood transfusions for patients admitted to the haematology ward: A complete audit cycle and quality improvement project | Helen Perera | ![]() |
![]() |
|||
230-P | Successful renal transplantation in Jehovahs Witnesses shouldnt we apply our approach to blood refusers to all patients, to reduce risks associated with blood transfusions? | Charlotte Phillips | ![]() |
![]() |
|||
231-P | Contribution of the British Bone Marrow Registry (BBMR) to the UK transplant activity in 2007 and investigation of final donors in this year | Yousif Aawsaj | ![]() |
![]() |
|||
232-P | The use and outcomes of prothrombin complex concentrate in a district general hospital | julie blundell | ![]() |
![]() |
|||
238-P | High recruitment into interventional clinical trials is possible in the setting of a district general trust (DGT): Results of a short prospective audit | LAVINIA DAVEY | ![]() |
![]() |
|||
255-P | Haemoglobinopathy screening pathways and attitudes to opportunistic screening for haemoglobinopathies | Meghna Ruparelia | ![]() |
![]() |
|||
257-P | Safety and efficacy of elective automated red cell exchange transfusion programmes for patients with sickle cell disease | Paul Miller | ![]() |
![]() |
20-22 April 2015 Edinburgh
COLLECT YOUR PRINTED POSTER ON-SITE AT THE REGISTRATION DESK |
---|
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|